Want to see NVNO full AI Analyst Report?
NVNO Stock Chart & Stats
$10.39
$0.28(2.69%)
At close: 4:00 PM EDT
$10.39
$0.28(2.69%)
Day’s Range― - ―
52-Week Range$8.67 - $179.55
Previous Close$10.77
Volume2.86K
Average Volume (3M)589.93K
Market Cap
$6.94M
Enterprise Value-$17.70
Total Cash (Recent Filing)$24.93M
Total Debt (Recent Filing)$603.00K
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1147.01
Shares Outstanding667,669
10 Day Avg. Volume395,892
30 Day Avg. Volume589,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$30.00Price Target Upside188.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-35
Revenue Forecast (FY)$7.00M
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone / Pivotal TrialReceiving an FDA IDE for a U.S. pivotal TAVVE trial is a durable de-risking event: it enables a structured pathway toward potential approval and commercialization, creates a two-stage clinical program to generate robust evidence, and materially improves the company’s ability to convert R&D into a marketable therapy over the next 2–4 years.
Intellectual Property ProtectionA foundational U.S. patent strengthens long-term competitive barriers by protecting core device technology and supporting exclusivity in a large, under-served venous valve market; durable IP reduces the risk of direct replication, enhances licensing or partnership leverage, and supports sustained pricing power if commercialized.
Low Financial LeverageVery low debt relative to equity gives the company structural financial flexibility to execute a multi-year clinical program without interest burden, reducing bankruptcy risk and preserving strategic optionality for financing, partnerships or staged investment as it attempts to move from R&D to commercialization.
Bears Say
Pre-revenue Business ModelBeing pre-revenue is a long-duration constraint: the company has yet to demonstrate a scalable commercial model or product-market fit. Until clinical success and reimbursement pathways are proven, the business depends on trial outcomes and external funding, limiting durable free cash generation and long-term self-sustainability.
Persistent Cash BurnSustained negative operating and free cash flow signals ongoing reliance on financing to fund trials and operations; even with current runway into Q3 2027, continued cash burn raises dilution risk and constrains strategic choices, making long-term execution contingent on successful fundraises or partnerships.
Erosion Of Equity And Poor ReturnsMeaningful declines in equity and assets alongside deeply negative ROE reflect persistent capital erosion from operating losses. This undermines financial resilience, reduces ability to invest in commercialization, and signals low capital efficiency until the firm achieves positive margins and profitable scaling.
enVVeno Medical News
NVNO FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was $8.67 and its highest was $179.55 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is $6.94M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is Nov 05, 2026 which is in 97 days.
How were enVVeno Medical’s earnings last quarter?
Currently, no data Available
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Undervalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 667,669 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in NVNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
NVNO Stock 12 Month Forecast
Average Price Target
$30.00
▲(188.74% Upside)
Technical Analysis
Ownership Overview
9.46% Insiders
1.91% Mutual Funds
0.01% Other Institutional Investors
87.67% Public Companies and
Individual Investors